Immunovaccine Inc.
TSX VENTURE : IMV

Immunovaccine Inc.

June 11, 2010 13:45 ET

Immunovaccine Inc.: Warwick Kimmins Science Scholarship Awarded

HALIFAX, NOVA SCOTIA--(Marketwire - June 11, 2010) - Immunovaccine Inc. (TSX VENTURE:IMV), a vaccine development company, has awarded the $1,000 Warwick Kimmins Science Scholarship today to Melissa Powers. Melissa is graduating from Sackville High School in N.S. and will be attending Dalhousie University in September.

"Melissa's winning essay on her quest for a cure for Alzheimer's disease was compassionate and insightful," said Brian Lowe, Vice President of Immunovaccine.

Alzheimer's disease is of particular interest to Melissa as both of her grandparents suffer from this devastating illness. She also has first-hand experience with Alzheimer's disease patients through the local nursing home, at which she volunteers.

"In addition to being an excellent student who gives back to her community, Melissa has a genuine interest in scientific research. We are happy to offer her this scholarship and wish her all the best in pursuing her Bachelor of Science degree at Dalhousie," continued Lowe.

The scholarship is in memory of IMV's founder, Dr. Warwick Kimmins. Dr. Kimmins was the former Dean of the Faculty of Science at Dalhousie University and was instrumental in bringing Immunovaccine to where it is today.

About Immunovaccine

Immunovaccine Inc. (TSX VENTURE:IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines.

Contact Information